Argenx Se (ARGX) Other Operating Expenses (2019 - 2026)
Argenx Se's (ARGX) quarterly Other Operating Expenses came in at $387.0 million in Q2 2026, down 72.72% YoY from $1.4 billion in Q2 2025, and up 419.83% on a QoQ basis from -$121.0 million in Q1 2026.
Argenx Se (ARGX) Other Operating Expenses (2019 - 2026) Analysis & Trends
Argenx Se (ARGX) has 8 years of Other Operating Expenses data on file, last reported at $387.0 million in Q2 2026.
- Quarterly Other Operating Expenses fell 72.72% year-over-year to $387.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (up 33.97% YoY) and the FY2025 annual result came in at $463.1 million, up 97.1% from the prior year.
- Other Operating Expenses climbed to $387.0 million in Q2 2026, from -$121.0 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $1.5 billion in Q3 2025 to a low of -$153.2 million in Q4 2025.
- A 5-year average of $142.2 million and a median of -$31.2 million in 2023 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2022 — Other Operating Expenses plunged 1346200.0% — and 2025, when it surged 2731.95%.
- Tracing ARGX's Other Operating Expenses over 5 years: stood at -$13.5 million in 2022, then slumped by 206.51% to -$41.3 million in 2023, then tumbled by 81.77% to -$75.0 million in 2024, then tumbled by 104.27% to -$153.2 million in 2025, then jumped by 352.59% to $387.0 million in 2026.
- The last three Other Operating Expenses figures came in at $387.0 million (Q2 2026), -$121.0 million (Q1 2026), and -$153.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 387.00 Mn |
| Mar 31, 2026 | -121.00 Mn |
| Dec 31, 2025 | -153.21 Mn |
| Sep 30, 2025 | 1.50 Bn |
| Jun 30, 2025 | 1.42 Bn |
| Mar 31, 2025 | -81.00 Mn |
| Dec 31, 2024 | -75.01 Mn |
| Sep 30, 2024 | -61.05 Mn |
| Jun 30, 2024 | -53.90 Mn |
| Mar 31, 2024 | -44.97 Mn |
| Dec 31, 2023 | -41.27 Mn |
| Sep 30, 2023 | -36.74 Mn |
| Jun 30, 2023 | -25.64 Mn |
| Mar 31, 2023 | -18.60 Mn |
| Dec 31, 2022 | -13.46 Mn |
| Sep 30, 2022 | -10.26 Mn |
| Jun 30, 2022 | -5.01 Mn |
| Mar 31, 2022 | -1.37 Mn |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | 1,000.00 |